To print: Select File and then Print from your browser's menu
---------------------------------------------------------------------------------------
Title: FDA Approves Duloxetine HCl for the Management of Fibromyalgia
URL: http://www.pslgroup.com/dg/223932.htm
Doctor's Guide
June 16, 2008

NEW YORK -- June 16, 2008 -- The US Food and Drug Administration (FDA) has approved duloxetine HCl (Cymbalta) for the management of fibromyalgia, a chronic widespread pain disorder. Duloxetine HCl is a serotonin-norepinephrine reuptake inhibitor indicated to reduce pain in patients with fibromyalgia.

Duloxetine HCl was proven efficacious in 3 pivotal 3-month clinical trials involving 874 patients with fibromyalgia. In both studies, duloxetine HCl reduced pain at the study's endpoint compared with placebo as measured by the Brief Pain Inventory (BPI) 24-hour average pain scale.

Significant improvement in pain for duloxetine HCl versus placebo was observed in the first week of each study. Fifty-one percent and 55% of patients on duloxetine HCl had a 30% improvement on the BPI at the study's endpoint. In addition, 65% and 66% of patients taking duloxetine HCl 60 mg daily reported feeling better at the study's endpoint as measured by the Patient Global Impression of Improvement (PGI-I). Duloxetine HCl 60 mg was also superior to placebo on the Fibromyalgia Impact Questionnaire Total Score.

In 4 pooled studies, the most commonly observed adverse events in duloxetine HCl-treated patients with fibromyalgia were nausea, dry mouth, constipation, decreased appetite, sleepiness, increased sweating, and agitation. In the placebo-controlled clinical trials, the overall discontinuation rates due to adverse events for duloxetine HCl versus placebo were 20% and 12%, respectively.

The approval marks the fourth disorder that the FDA has approved for duloxetine HCl. In addition to fibromyalgia, duloxetine HCl is approved for the management of diabetic peripheral neuropathic pain (DPNP) and the treatment of major depressive disorder and generalised anxiety disorder, all in adults aged 18 years and older.


SOURCE: Chamberlain Healthcare Public Relations

---------------------------------------------------------------------------------------------
Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.
---------------------------------------------------------------------------------------------
This news story was printed from *Doctor's Guide to the Internet*
located at http://www.docguide.com
---------------------------------------------------------------------------------------

Return to News Story Page

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 1998 P\S\L Consulting Group Inc.
All rights reserved.